Lilly invests up to $370M in OmniAb ion channel partnership; Slate and Fulcrum to merge
Eli Lilly has entered a collaboration and licensing agreement with OmniAb focused on ion channels, with potential payments reaching $370 million. Separately, Slate and Fulcrum are pursuing a reverse merger. The deals highlight ongoing activity in biotech partnerships and corporate restructuring.
Related stories
Biohaven partners with SK Biopharmaceuticals on epilepsy drug in $795M deal · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger.” Browse more stories.